Quantcast

Latest Psoriasis Stories

2014-07-10 12:30:51

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ -- On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD [http://biocad.ru/en ]. The Company is developing a unique project called MabNext [http://biocad.ru/en/science ]. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune...

2014-07-10 10:20:50

University of Rochester Medical Center URMC-led study offers hope for atopic dermatitis sufferers An investigational medication shows promise in treating the most common skin disorder, often referred to as eczema or atopic dermatitis, according to a study published July 9 in the New England Journal of Medicine. The findings could eventually bring significant relief for many who suffer intense itching and other troubling features of atopic dermatitis, according to the study's lead...

2014-07-09 16:28:56

- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1] EAST HANOVER, N.J., July 9, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). Secukinumab met all primary and key secondary...

2014-07-09 08:28:45

DUBLIN, July 9, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3pfrzt/frontier_pharma) has announced the addition of the "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed...

2014-07-09 08:28:16

Psoriasis Foundation will drive efforts to cure psoriatic disease, help those affected PORTLAND, Ore., July 9, 2014 /PRNewswire-USNewswire/ -- National Psoriasis Foundation will double the number of researchers studying psoriasis and psoriatic arthritis while also cutting in half the number of people who say these chronic conditions are a problem in their daily lives as part of its new five-year strategic plan and mission to cure psoriatic disease and improve the lives of those affected....

2014-07-07 16:02:23

European League Against Rheumatism Low dosing of infliximab does not appear to alter treatment response or adherence Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit. Further data revealed that, in the case of the TNFα inhibitor...

2014-07-03 11:58:33

The JAMA Network Journals Bottom Line: Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension may also increase the risk of psoriasis. Author: Shaowei Wu, M.D., Ph.D., of Brown University, Providence, Rhode Island, and colleagues. Background: Psoriasis is an immune-related chronic disease that affects about 3 percent of the U.S. population. The...

2014-07-03 08:23:24

- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical leader (Euronext: UCB), and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia(®) (certolizumab pegol) in dermatology. This collaboration aims...

2014-06-26 23:02:08

Patient advocacy group teams with The Dermatologist to educate healthcare providers on the specifics of psoriasis research and treatment. Malvern, PA (PRWEB) June 26, 2014 The Dermatologist, a leading publication in the field of dermatology, is proud to announce a collaboration with the National Psoriasis Foundation, the world’s leading patient advocacy organization dedicated to the 7.5 million Americans with psoriasis and psoriatic arthritis, to educate dermatologists on the latest...

2014-06-26 08:28:32

NPF Psoriatic Arthritis Project to improve diagnosis, care and treatment for millions PORTLAND, Ore., June 26, 2014 /PRNewswire-USNewswire/ -- Millions of Americans with psoriatic arthritis--a serious disease that causes pain, swelling and stiffness of the joints and tendons, and can result in joint damage if left untreated--struggle to get the health care and treatments they need to manage their condition. National Psoriasis Foundation plans to change that by launching the largest...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related